Market Analysis – Drug Therapy for Cancer Treatment trends in the Global Market

United States (U.S.) Relative Survival trend from 1990 to 2010

Insight

The graph displays the survival rates of the people across all ages, races, and gender have steadily improved over the past 20 years.  Two-thirds of Americans diagnosed with cancer now live at least five years, compared to just over half in 1990. Although the changes are incremental year to year, cumulatively, more patients are gaining years of life.

Within tumors, survival rates vary by age and ethnic group. For instance, between 1990-95 and 2005-10, five-year survival rates improved approximately 55% more for patients aged 50-64 than for patients aged 75-85.

United States (U.S.) Oncology Market Growth from 2010-2015

Insight

The graph shows that the U.S. cost of oncology medicines has increased in the past five years by 73%, primarily driven by new medicines. The total cost of oncology medicines rose $15.9Bn to $37.8Bn in the U.S. between 2010 and 2015.

Ex-U.S. Oncology Market Growth from 2010-2015

Insight

The graph shows that the Outside of the U.S., the uptake of new therapies and more widespread use of older medicines is driving oncology cost growth.

Outside the U.S., oncology costs increased $13.8Bn to $42.3Bn between 2010 and 2015.

Potential Combination Therapies launching by 2021 by the Major Players

Insight

The graph shows the potential combination Therapies launching by 2021.  Among these, Roche is developing the largest number of combinations. Only Roche, BMS, AZ, and Janssen are studying combinations of an NME and an existing agent that are both produced by a single manufacturer. Combining an NME with another manufacturer’s in-line product, for example, constrains pricing flexibility and complicates promotion.

Also, other manufacturers have multiple combos such as agents from two or more manufacturers. Combinations including new agents represent new levels of development and marketing complexity.

Sales of the 10 leading companies in the global cancer market 2010* and 13 best selling cancer drugs

Insight

The graph displays the Sales of the 10 leading companies in the global cancer market 2010. Also, the graph shows the 13 best selling cancer drugs in the global market.

Global Oncology Costs and Growth, 2010-2020 (i.e., Market Forecast)

Insight

The graph shows the Global Oncology Costs and Growth from the year 2010-2020.

Oncology cost growth is expected in the 7.5% to 10.5% range annually through 2020, when global oncology costs will exceed $150 billion.

Major Players

The technology area is quite active, and following companies seem to be working in the domain, and they might be interested in proposed technology:

• Novartis
• Roche
• Takeda
• Pfizer
• Sanofi-Aventis
• Eli Lilly
• AstraZeneca
• Johnson & Johnson
• Bristol-Myers Squibb
• Merck & co.
• Teva
• Janssen

About Effectual Services

Effectual Services is an award-winning Intellectual Property (IP) management advisory & consulting firm offering IP intelligence to Fortune 500 companies, law firms, research institutes and universities, and venture capital firms/PE firms, globally. Through research & intelligence we help our clients in taking critical business decisions backed with credible data sources, which in turn helps them achieve their organisational goals, foster innovation and achieve milestones within timelines while optimising costs.

We are one of the largest IP & business intelligence providers, globally serving clients for over a decade now. Our multidisciplinary teams of subject matter experts have deep knowledge of best practices across industries, are adept with benchmarking quality standards and use a combination of human and machine intellect to deliver quality projects. Having a global footprint in over 5 countries helps us to bridge boundaries and work seamlessly across multiple time zones, thus living to the core of our philosophy - Innovation is global, so are we !!!

Follow Us: LinkedIn, Twitter